These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 10428081

  • 1. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
    Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL.
    J Neurochem; 1999 Aug; 73(2):821-9. PubMed ID: 10428081
    [Abstract] [Full Text] [Related]

  • 2. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.
    Dautzenberg FM, Wille S, Lohmann R, Spiess J.
    Proc Natl Acad Sci U S A; 1998 Apr 28; 95(9):4941-6. PubMed ID: 9560207
    [Abstract] [Full Text] [Related]

  • 3. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 4. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.
    Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA.
    Mol Endocrinol; 1997 Dec 15; 11(13):2048-53. PubMed ID: 9415408
    [Abstract] [Full Text] [Related]

  • 5. Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding.
    Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM.
    J Neurochem; 1999 Jan 15; 72(1):388-95. PubMed ID: 9886092
    [Abstract] [Full Text] [Related]

  • 6. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 15; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 7. A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity.
    Perrin MH, DiGruccio MR, Koerber SC, Rivier JE, Kunitake KS, Bain DL, Fischer WH, Vale WW.
    J Biol Chem; 2003 May 02; 278(18):15595-600. PubMed ID: 12611895
    [Abstract] [Full Text] [Related]

  • 8. Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart.
    Dautzenberg FM, Higelin J, Brauns O, Butscha B, Hauger RL.
    Mol Pharmacol; 2002 May 02; 61(5):1132-9. PubMed ID: 11961131
    [Abstract] [Full Text] [Related]

  • 9. Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction.
    Assil IQ, Qi LJ, Arai M, Shomali M, Abou-Samra AB.
    Biochemistry; 2001 Feb 06; 40(5):1187-95. PubMed ID: 11170443
    [Abstract] [Full Text] [Related]

  • 10. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.
    Dautzenberg FM, Huber G, Higelin J, Py-Lang G, Kilpatrick GJ.
    Neuropharmacology; 2000 Jun 08; 39(8):1368-76. PubMed ID: 10818253
    [Abstract] [Full Text] [Related]

  • 11. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
    Myers DA, Trinh JV, Myers TR.
    Mol Cell Endocrinol; 1998 Sep 25; 144(1-2):21-35. PubMed ID: 9863624
    [Abstract] [Full Text] [Related]

  • 12. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep 25; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 13. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 25; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 14. High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1.
    Rühmann A, Bonk I, Köpke AK.
    Peptides; 1999 Nov 25; 20(11):1311-9. PubMed ID: 10612445
    [Abstract] [Full Text] [Related]

  • 15. The role of the fourth extracellular domain of the rat corticotropin-releasing factor receptor type 1 in ligand binding.
    Sydow S, Flaccus A, Fischer A, Spiess J.
    Eur J Biochem; 1999 Jan 25; 259(1-2):55-62. PubMed ID: 9914475
    [Abstract] [Full Text] [Related]

  • 16. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach.
    Liaw CW, Grigoriadis DE, Lovenberg TW, De Souza EB, Maki RA.
    Mol Endocrinol; 1997 Jun 25; 11(7):980-5. PubMed ID: 9178757
    [Abstract] [Full Text] [Related]

  • 17. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.
    Ardati A, Goetschy V, Gottowick J, Henriot S, Valdenaire O, Deuschle U, Kilpatrick GJ.
    Neuropharmacology; 1999 Mar 25; 38(3):441-8. PubMed ID: 10219982
    [Abstract] [Full Text] [Related]

  • 18. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 19. Urocortin is the principal ligand for the corticotrophin-releasing factor binding protein in the ovine brain with no evidence for a sauvagine-like peptide.
    Baigent SM, Lowry PJ.
    J Mol Endocrinol; 2000 Feb 06; 24(1):53-63. PubMed ID: 10656997
    [Abstract] [Full Text] [Related]

  • 20. An oxidation resistant radioligand for corticotropin-releasing factor receptors.
    Assil IQ, Shomali ME, Abou-Samra AB.
    Peptides; 2001 Jul 06; 22(7):1055-61. PubMed ID: 11445234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.